Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,626 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- OncoTree
- BREAST
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05241405 | Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer(QISEIN) | recruiting | N/A | 354 | Centre Francois BaclesseOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04258280 | Improving Genetic Counseling for BRCA+ Mothers(PCS IV) | recruiting | N/A | 200 | Georgetown UniversityOTHER | 1 | Sep 27, 2024 |
| clinicaltrials |
| NCT06026631 | Lipidomic Characterization in Non-metastatic Breast Cancer Women Undergoing Surgery: a Pilot Study.(BreCaLip) | active not recruiting | N/A | 65 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06185972 | Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Breast Cancer | recruiting | Phase 2 | 200 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06299202 | Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy(CERePred) | recruiting | N/A | 100 | Hospices Civils de LyonOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06615466 | Super-Hypofractionated Partial Breast Irradiation | recruiting | N/A | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06613373 | An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer | not yet recruiting | Phase 4 | 30 | Jiangsu Famous Medical Technology Co., Ltd.INDUSTRY | 0 | Sep 25, 2024 | clinicaltrials |
| NCT04344496 | East Asian Breast Cancer Genome Atlas and Recurrence Risk Prediction | recruiting | — | 2,000 | National Taiwan University HospitalOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT04547907 | A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | recruiting | Phase 3 | 688 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06489158 | Observation of Exhaled VOC Biomarkers Characteristics in Admitted Women with Breast Ultrasound BI-RADS 4 Grade | recruiting | — | 168 | Peking Union Medical College HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06605521 | To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients | recruiting | — | 300 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04539496 | A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 402 | Sihuan Pharmaceutical Holdings Group Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04875351 | Breast Cancer Index (BCI) Registry | active not recruiting | — | 3,465 | Biotheranostics, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05019690 | Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 29 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05772390 | Partial Breast Re-irradiation in Women in Women with Locally Recurrent Breast Cancer Previously Treated with Conservative Surgery and Whole Breast Irradiation(PBReI) | recruiting | Phase 2 | 68 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05841186 | Correlation of Timing of Pegfilgrastim Administration and PIBP. | recruiting | N/A | 156 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06272799 | Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.(ATD) | recruiting | — | 160 | Regina Elena Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06342037 | NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial(TONIC-3) | recruiting | Phase 2 | 60 | The Netherlands Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06378944 | Selective Sentinella Lymph Node Biopsy with Indocyanine Green in Patients with Breast Cancer(INSEAN) | recruiting | — | 15,000 | Omphis FoundationOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06559696 | Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy | recruiting | Phase 3 | 722 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06575049 | Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery | not yet recruiting | — | 60 | Seoul National University HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06586866 | JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases | not yet recruiting | Phase 2 | 25 | JenKem Technology Co., Ltd.INDUSTRY | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06592560 | Asprosin in Breast Cancer | not yet recruiting | — | 84 | Marina Hanna Thabet GhobrialOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06595966 | Exploratory Research on Constructing a Computational Biological Model Based on NGS for MRD After Breast Cancer Surgery | recruiting | — | 80 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06331169 | Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer | recruiting | Phase 1 | 42 | Fudan UniversityOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06578286 | ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | not yet recruiting | Phase 2 | 44 | Fudan UniversityOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT06578299 | Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer | not yet recruiting | Phase 4 | 100 | Fudan UniversityOTHER | 0 | Aug 29, 2024 | clinicaltrials |
| NCT02802553 | Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions | active not recruiting | N/A | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT03827317 | HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer | recruiting | N/A | 24 | Imperial College LondonOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06039956 | De-escalating Axillary Surgery in Breast Cancer Patients in Nigeria | not yet recruiting | N/A | 100 | Nova Scotia Health AuthorityOTHER | 0 | Aug 22, 2024 | clinicaltrials |
| NCT06566729 | MRD in High-risk EBC | active not recruiting | — | 125 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06566937 | The Effectiveness of E-health Intervention in Improving Mental Health Outcomes Among Breast Cancer Patients | recruiting | N/A | 114 | National University of MalaysiaOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06197581 | Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer(RADIOCOM) | recruiting | N/A | 148 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06176534 | Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial | recruiting | Phase 2 | 240 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06561646 | To Evaluate the Effectiveness and Safety of the Single-port Robotic-assisted Breast Surgery in Breast Cancer | not yet recruiting | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06548178 | T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer | not yet recruiting | Phase 2 | 242 | Fudan UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06548919 | Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer | recruiting | — | 450 | SciClone PharmaceuticalsINDUSTRY | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06549920 | Danish Breast Cancer Group Internal Mammary Node Study(DBCG IMN) | active not recruiting | N/A | 7,630 | Danish Breast Cancer Cooperative GroupOTHER | 0 | Aug 12, 2024 | clinicaltrials |
| NCT06547476 | Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed | not yet recruiting | Phase 2 | 40 | Guangdong Provincial People's HospitalOTHER | 0 | Aug 9, 2024 | clinicaltrials |
| NCT04679454 | Single Fraction Preoperative Radiotherapy for Early Stage Breast Cancer | recruiting | N/A | 79 | European Institute of OncologyOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT05710666 | Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) | active not recruiting | Phase 2 | 11 | Cancer Trials IrelandNETWORK | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06531447 | First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients | active not recruiting | Phase 2 | 200 | The National Center of Oncology, AzerbaijanOTHER_GOV | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT03900637 | PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate | active not recruiting | Phase 2 | 122 | Seoul National University HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06503380 | Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer | recruiting | — | 1,000 | Fudan UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03577197 | Southeast Netherlands Advanced Metastatic Breast Cancer Registry(SONABRE) | recruiting | — | 7,000 | Academisch Ziekenhuis MaastrichtOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06508216 | A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer(COMPASS-TNBC) | recruiting | Phase 1 / Phase 2 | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06236269 | HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan(ACROSS-TROP2) | recruiting | Phase 2 | 50 | SOLTI Breast Cancer Research GroupOTHER | 1 | Jul 19, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Oct 1, 2024source: clinicaltrials